Table 5: Changes from Week 26 Baseline to Week 52 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward) Patients treated with a 2 mg dose of EGRIFTA (1 mg/formulation) for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively)
It will be imperative that single-unit electrophysiology approaches are used to analyze the cell-specific details of neuronal responses downstream of stimulation, but also population-level responses will have to be collected using tools such as tetrodes, array electrodes, silicone probes, or even fiber photometry and deep tissue endoscopy
Market growth increased biologic therapies across healthcare treatment plans
BPC-157s application duration in studies usually depends on the specific research objectives
4 Single-dose prefilled pens 4 x 10 mg/0.5 mL prefilled pens Rx Only For Subcutaneous Use Dispense enclosed Medication Guide to each patient
Beta thymosins as actin-binding peptides
